Alzheimer's Disease treatment: a novel approach

-
Alzheimer's disease (AD) is particularly devastating since there is no cure, no way to prevent it and no proven way to slow its progression.
-
Management of AD represents a huge unmet need; thus, discovery and development of more effective therapies are critical for worldwide public health and health-care systems.
-
Novel strategy for symptomatic & disease-modifying treatment of Alzheimer's disease hitting two targets, epigenetic (HDAC) and non-epigenetic (PDES). Proof of Concept using reference compounds (vorinostat and tadalafil).
-
In vitro, using primary neuronal cultures: synergistic effect on epigenetic mark (histone acetylation).
-
Ex vivo, using hippocampal slices from AD mice (APP/PS1): synergistic effect in long term potentiation (LTP).
-
In vivo, using AD mice (Tg2576): behavior studies and AD pathological marks.
-
-
Novel proprietary compounds, first‐in class dual inhibitors (HDAC and PDE5) show safety and efficacy in reversing AD phenotype using transgenic mice (APP/PS1, Tg2576).
Novel target in CNS: GluN3A in HD and drug abuse

-
There is an unmet need for effective therapeutic strategies in Huntington's disease (HD) and drug abuse.
-
GluN3A is a novel target that regulates synapse plasticity and neuronal connectivity.
-
Its expression is reactivated in CNS pathologies including HD, cocaine and alcohol abuse.
-
Proof of Concept: Knock-Out mice in HD and shRNA in drug abuse.
-
Safety: lacking in healthy adult brain.
-
Contacta con nosotros |
Contacto:
Centro de Investigación Médica Aplicada (CIMA) Avenida Pío XII, 55 31008 Pamplona España +34 948 194 700 cima@unav.es |